VAXINANO
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
Vaxinano is redefining vaccine delivery with its proprietary STELLAR-NP™ muco-adhesive platform, which converts conventional injectable vaccines into needle-free, thermostable formulations suitable for intranasal or oral administration. By eliminating cold-chain constraints and simplifying administration, we unlock global market access—especially in regions where traditional logistics and healthcare infrastructure are limited. The company signed multiple collaborations and ou-license one product in leishmaniasis disease in 2024.



